Multifactorial diseases pose a significant global health challenge, impacting economically developed nations with conditions ...
Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: Initial results of the FIERCE study. Complementary value ...
Nearly 50 new cancer therapies are approved every year. While this positive trend is a huge benefit for patients, Altuna Akalin, PhD, head of the bioinformatics and omics data science technology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., a spatial multi-omics innovator accelerating biological discovery and new drug development, today announced that it will present new spatial ...
SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world ...
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia ...
Sapio Sciences, which uses the science-aware TM lab informatics platform, entered into a partnership with Ultima Genomics that company officials will make multi-omics workflows more accessible and ...
Profusa Inc. PFSA shares rose in Monday premarket trading after the company announced a $30 million Letter of Intent. The ...
We compared the TuPro melanoma cohort (n = 98), which received multi-omics–guided selection of adjuvant, standard of care and beyond standard-of-care therapies in patients with advanced melanoma, to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results